Biote Corp. Announces CEO Resignation, Appoints Interim CEO and Executive Chairman, Reaffirms 2026 Guidance
Summary
Biote Corp. announced the resignation of its CEO, Bret Christensen, and appointed CFO Robert Peterson as Interim CEO. Chairman Marc Beer will assume the role of Executive Chairman, and the company reaffirmed its full-year 2026 guidance.
Key Events
-
CEO Resignation
Bret Christensen resigned as CEO, effective June 8, 2026, citing family and personal reasons. He will remain on the Board as a Class III director and received a stock option for 130,000 shares.
-
Interim CEO Appointment
Robert Peterson, current CFO and Chief Business Officer, was appointed Interim CEO and a director, effective June 8, 2026. His compensation for the interim role is yet to be determined.
-
Executive Chairman Appointed
Marc Beer, the current Chairman, was appointed Executive Chairman, effective June 8, 2026. He will receive an annual base compensation of $521,200, an annual performance bonus up to 85% of base, and a stock option award for 114,157 shares.
-
2026 Guidance Reaffirmed
The company reaffirmed its full-year 2026 guidance, projecting revenue above $190 million and Adjusted EBITDA above $38 million, with a return to procedure revenue growth in the second half of the year.
Analysis
This filing details a significant leadership overhaul at biote Corp. The departure of the CEO, Bret Christensen, for personal reasons, coupled with the appointment of the current CFO as Interim CEO and the Chairman stepping into an Executive Chairman role, indicates a major transition. The reaffirmation of 2026 guidance for revenue and Adjusted EBITDA is a critical piece of information, providing a degree of stability amidst these changes, especially given the company's recent reports of declining financial performance and cash reserves. The substantial compensation package for the new Executive Chairman and equity awards for both the outgoing and incoming leadership are notable for a company of this market capitalization.
At the time of this filing, BTMD was trading at $2.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $65.2M. The 52-week trading range was $1.27 to $4.75. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.